Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Deferred Taxes Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Cresco Labs (CRLBF) Gains from Equity Investments (2020 - 2021)

Cresco Labs filings provide 2 years of Gains from Equity Investments readings, the most recent being -$1.2 million for Q1 2021.

On a quarterly basis, Gains from Equity Investments fell 730.56% to -$1.2 million in Q1 2021 year-over-year; TTM through Dec 2021 was -$1.2 million, a N/A change, with the full-year FY2021 number at -$1.2 million, down 201.27% from a year prior.
Gains from Equity Investments hit -$1.2 million in Q1 2021 for Cresco Labs, down from $927000.0 in the prior quarter.
In the past five years, Gains from Equity Investments ranged from a high of $927000.0 in Q4 2020 to a low of -$1.2 million in Q1 2021.